- Adjunct Professor, Global Health
- Professor, Microbiology
- Chair, Microbiology
Center for Infectious Disease Research
307 Westlake Avenue N, Suite 500
Seattle, WA 98109
Select from the following:
David Sherman is a Professor and Department Chair of the Department of Microbiology in the University of Washington School of Medicine in Seattle. He earned his PhD in Biochemistry from Vanderbilt University, and performed post-graduate work at the Rockefeller University and at Washington University in St. Louis. His laboratory studies the molecular genetics, systems biology and pathogenesis of M. tuberculosis, and is also engaged in drug discovery efforts for this important pathogen. Dr. Sherman played a lead role in the discovery and early development of the anti-TB agent pretomanid. In addition, his laboratory defined the mutation responsible for attenuation of the world’s most widely used vaccine, BCG. On a personal level, Dr. Sherman routinely leaps tall buildings in a single bound and completes 60-minute gourmet recipes in under 40 minutes. Children and dogs love him. He is far too modest to take pleasure from the fact that you are reading about him right now.
- PhD (Vanderbilt University)
- BA (University of California (Berkeley))
- Infectious Diseases
- Infectious Diseases (other than STDs)
ODELAM Rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis. Herricks T, Donczew M, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, Aitchison JD.Herricks T, et al. Elife. 2020 May 13;9:e56613. doi: 10.7554/eLife.56613.
Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge BB, Sherman DR, Chandrasekaran S.Ma S, et al. .mBio. 2019 Nov 12;10(6):e02627-19. doi: 10.1128/mBio.02627-19.mBio. 2019.
Nicotinamide Limits Replication of Mycobacterium tuberculosis and Bacille Calmette-Guérin Within Macrophages.
Simmons JD, Peterson GJ, Campo M, Lohmiller J, Skerrett SJ, Tunaru S, Offermanns S, Sherman DR, Hawn TR.Simmons JD, et al.J Infect Dis. 2020 Mar 2;221(6):989-999. doi: 10.1093/infdis/jiz541.J Infect Dis. 2020.
Peterson EJ, Ma S, Sherman DR, Baliga NS. Network analysis identifies Rv0324 and Rv0880 as regbulators of bedaquiline tolerance in Mycobacterium tuberculosis. Nat Microbiol. 2016 Jun; 1(8):16078. PMCID: PMC5010021.
Colangeli R, Jedrey H, Kim S, Conell R, Ma S, Chakravorty S, Sizemore E, Diem L Sherman DR, Mac Kenzie W, Alland D. Bacterial Factors That Predict Relapse After Anti-tuberculosis Therapy. N Engl J Med. 2018 Aug 30;379(9):823-833. PMID: 3015739.
Ragheb MN, Thomason MK, Hsu C, Nugent P, Gage J, Samadpour AN, Kariisa A, Merrikh CN, Miller SI, Sherman DR, Merrikh H. Inhibiting the Evolution of Antibiotic Resistance. Mol Cell. 2019 Jan 3;73(1):157-165.e5 PMID: 30449724.
Ma S, Jaipalli S, Larkins-Ford J, Aldridge BB, Sherman DR, Chandrasekaran S. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis. MBio. 2019 Nov 12; 10(6). Pii:e02627-19. doi: 10.1128/mBio.02627-19 PMID 31719182
Herricks T, Donczew D, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, Aitchison JD. ODELAM: Rapid sequence-independent detection of drug resistance by live cell imaging in clinical isolates of Mycobacterium tuberculosis. eLife 2020 May, 13;9 e56613. doi: 10.7554/eLife. PMID: 32401195 Free PMC article.